The global Continuous Glucose Monitoring Device Market size is expected to reach USD 12.18 billion by 2026 according to a new study by Polaris Market Research. The report “Continuous Glucose Monitoring Device Market Share, Size, Trends, Industry Analysis Report By Component (Transmitters & Receivers, Sensors, Insulin Pumps); By End-Use (Hospitals, Homecare Diagnostics); By Regions (North America, Europe, Asia Pacific, Middle East & Africa, Latin America); Segment Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Continuous Glucose Monitoring Device have witnessed tremendous growth in the recent past and this trend is expected to continue from 2020 to 2026. Health agencies as well as governments have issued health advisories which explicitly mention that people suffering from diabetes are at high risk of corona virus infection. Experts have also specifically mentioned that continuous monitoring of blood glucose levels to avoid worsening of conditions. CGM is expected to benefit from such trends.
In order to cope with the rising demand for COVID-19 tests, companies such as Abbot have customized their production lines and manufacturing schedules to produce corona virus test kits. However, such companies have stressed on the fact that the production of other products such as CGM will not be hampered. It is expected that there will be exponential rise in demand for CGM products in the next few years. As of now, healthcare has become of prime importance and there is rising importance of preventive healthcare. Ease of usage of CGM products, easy availability coupled with COVID-19 scare is expected to fuel the market growth.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/continuous-glucose-monitoring-market/request-for-sample
Although, point of care diagnostic procedures such as CGM proves to be very effective in delivering healthcare to all, they are an expensive affair for healthcare facilities dealing with high test volumes. This is expected to impede market’s growth in the cost sensitive undeveloped economies of the market. However, the introduction of cheap and cost-effective devices for point of care diagnoses is expected to gradually reduce the impact of this restraint over the forecast period.
The regulatory framework is one of the most restraining factors pertaining to pharmaceutical, biotechnology and medical technology industry. Absence of clear regulatory framework/guidelines for the diagnostic sector in developing countries such as India and China where the CGM market has great growth potential due to the presence of a large patient base is anticipated to impede growth in the coming years. The presence of such discrete and uncertain scenario about the regulations for CGM devices creates confusion among CGM manufacturers regarding commercialization.
North America emerged as the largest market in 2019 and the regional market is expected to dominate the market up to the end of the forecast period i.e. 2026. Strong presence of market participants, high awareness regarding device usage and high inclination towards preventive healthcare are some of the factors benefitting the regional market growth.
Companies such as Senseonics Holdings, Inc., Insulet Corporation, Bayer AG, Ypsomed Holding AG, LifeScan, Novo Nordisk, Medtronic PLC, Dexcom Inc., Abbott Diagnostics Inc., and Roche Diagnostics are some of the key players operating in the Continuous Glucose Monitoring Device Market.
Request For Toc: https://www.polarismarketresearch.com/industry-analysis/continuous-glucose-monitoring-market/toc
The global Continuous Glucose Monitoring Device Market size is expected to reach USD 12.18 billion by 2026 according to a new study by Polaris Market Research.
Health agencies as well as governments have issued health advisories which explicitly mention that people suffering from diabetes are at high risk of corona virus infection.
It is expected that there will be exponential rise in demand for CGM products in the next few years.
Although, point of care diagnostic procedures such as CGM proves to be very effective in delivering healthcare to all, they are an expensive affair for healthcare facilities dealing with high test volumes.
However, the introduction of cheap and cost-effective devices for point of care diagnoses is expected to gradually reduce the impact of this restraint over the forecast period.
Request for a sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/continuous-glucose-monitoring-market/request-for-sample The regulatory framework is one of the most restraining factors pertaining to pharmaceutical, biotechnology and medical technology industry.
Patient handling equipment is an assistive devices allowing the hospitalized patients to transfer to other places who lack the strength to control the body movements.
Patient handling equipment’s are specially designed in helping the patients in hospitals, nursing homes and medical centers with some mobility.
The equipment’s are cost efficient than retrofitting, assures increased productivity of care givers and ensures patient’s safety.
The manual patient handling devices are based on mechanical assessment of patients to ensure safety to the patient, caregiver and rehabilitation goals.
Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/700Increasing disabilities post surgeries is expected to drive the patient handling equipment marketAccording to the World Health Organization, in 2017, an estimated 1.8 million patients suffered from some form of disability in 2015 and then approximately globally each year, the number of disabilities being expected to increase to 2.43 million patients by 2030.
Bone and Joint Initiative, in 2014, an estimated 4.5 million sports were related to musculoskeletal injuries recorded in the U.S., with millions suffering from spine deformities, cancers of bones and connective tissues and congenital conditions, thus adding up to the market growth.
Global cell-free DNA testing market was valued US$ 85.3 Mn in 2017 and is expected to reach US$ 439.2 Mn by 2026, at a CAGR of 22.73 % during a forecast period.
The non-invasive prenatal test is a new technology being used to assess the risk of a pregnant woman's and taking a sample of blood from the vein rather than inserting a needle into the uterus similar to amniocentesis.
The cell-free DNA testing is used in many fields such as gynecology, oncology, and transplantation to identify mutations in cancer patients and identify various chromosomal abnormalities in the fetus, to know the gender of the fetus.
Health damaging lifestyle actions such as the increased use of tobacco & alcohol, lack of physical activity, poor eating habits or heavy consumption of fast foods, are the major driving factors for chronic diseases.
The growth of cell-free fetal DNA testing market is mainly expected to exact and effective results for aneuploidy screening.
Down syndrome is generally caused by an error in cell division called “nondisjunction.” It caused when abnormal cell division results in extra genetic material from chromosome 21.
The study presents a deep-dive assessment of the current growth dynamics, major avenues in the estimation year of 2029 and key prospects over the forecast period 2020-2025.The global antibacterial drugs market is anticipated grow at a CAGR of 1.5% over the forecast period 2020-2025.
Extensive rounds of primary and a comprehensive secondary research have been leveraged by the analysts at Fact.MR to arrive at various estimations and projections of the antibacterial drugs market, both at global and regional levels.
The analysts have used numerous industry-wide prominent business intelligence tools to consolidate facts, figures, and market data into revenue estimations and projections in the antibacterial drugs market.The antibacterial drugs market analysis report offers assessment of prevailing opportunities in various regions and evaluates their shares of revenue by the end of different years of the assessment period.Key regions covered comprise:• North America (Canada, US)• Latin America (Argentina, Mexico)• Europe (NORDIC, UK)• APEJ (China, India)• MEA and JapanAfter reading the antibacterial drugs market report, readers get insight into:• Major drivers and restraining factors, opportunities and challenges, and the competitive landscape• New, promising avenues in key regions• New revenue streams for all players in emerging markets• Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions• Demand and uptake patterns in key industries of the antibacterial drugs market• New research and development projects in new technologies in key regional markets• Changing revenue share and size of key product segments during the forecast period• Technologies and business models with disruptive potentialYou can Request an Example Copy from here - https://www.factmr.com/connectus/sample?flag=S_id=4340To expand the understanding of opportunities in the global antibacterial drugs market report looks at close quarters into the opportunities and new avenues in following key segments:• By Equipment Type• By Region• By End-Users• By Sales ChannelsIn addition to understanding the demand patterns of various end users, the report on the antibacterial drugs market also enumerates trends expected to attract investments by other various associated industries.The evaluation of the competitive landscape in the antibacterial drugs market covers the profile of the following top players:• Johnson and Johnson• Bristol-Myers Squibb Company• Allergen Plc.• GlaxoSmithKline plc.The global antibacterial drugs market report offers detailed assessments and quantitative evaluations that shed light on numerous key aspects that have shaped its evolution over the historical period.
In coming years, some of the key aspects that will shape the growth prospects during the forecast period are objectively covered in the study.
The research report on the global market for diabetes drugs analyzes the present and future market scenario of the worldwide market.
Rapid rise in elderly population around the world and increasing incidence as well as commonness of diabetes such as Type 1 diabetes and Type 2 diabetes are following aspects likely to increase the growth of global market for Diabetes drugs over the period of forecast.Diabetes Drugs Market: Segmental Analysis & Regional OverviewRequest For Report Sample:https://www.researchreportinsights.com/report/upsample/120124589/Diabetes-Drugs-MarketThe research study categorizes the global market for diabetes drugs into disease type, therapy, channel of distribution, and region.On the basis of disease type, this report segregate the global diabetes drugs market intoImpaired Glucose Tolerance and Impaired Fasting Glycaemia, Type 1 Diabetes, Gestational Diabetes, and Type 2 Diabetes.
Based on channel of distribution, the study categorizes diabetes drugs market into online pharmacies, hospital pharmacies and Retail Pharmacies.
According to therapy, the research study divides the international diabetes drugs market into Sodium glucose co-transporter 2 (SGLT2) inhibitors, Glucagon-like peptide-1 (GLP-1) agonist, Insulin, and others, Dipeptidyl-peptidase-4 (DPP-4) inhibitors.Additionally, the Insulin lead the global market on the basis of revenue share in 2016.
Sodium glucose co-transporter 2 is expected to grow over the period of assessment owing to exclusivity and patents.
On the basis of region, the report bifurcates the worldwide market for diabetes drugs market into Asia Pacific, North America, the Middle East & Africa, Europe and Latin America.
